

Gout: Diagnosis and Management Committee meeting 2

Date: 18/09/2020

Location: Video-conference via Zoom

Minutes: Final

Committee members present:		
Aung Soe		(Present for notes 1 – 4)
Ed Roddy		(Present for notes 1 – 4)
Alastair Dickson		(Present for notes 1 – 4)
Sam Finnikin		(Present for notes 1 – 4)
Hugh Gallagher		(Present for notes 1 – 4)
Kelsey Jordan		(Present for notes 1 – 4)
Sarah Ryan		(Present for notes 1 – 4)
Jane Taylor		(Present for notes 1 – 4)

In attendance:		
Clifford Middleton	Guideline Commissioning Manager, NICE	(Present for notes 1 – 4)
Amber Hernaman	Project Manager, NGC	(Present for notes 1 – 4)
Sedina Lewis	Senior Research Fellow, NGC	(Present for notes 1 – 4)
Joseph Runicles	Information Specialist, NGC	(Present for notes 1 – 4)
Gill Ritchie	Guideline Lead, NGC	(Present for notes 1 – 4)
Audrius Stonkus	Research Fellow, NGC	(Present for notes 1 – 4)
Alexandra Bonnon	Health Economist, NGC	(Present for notes 1 – 4)
Sophia Kemmis-Betty	Senior Health Economist, NGC	(Present for notes 1 – 4)
Bruce Guthrie	External researcher, Professor of General Practice, University of Edinburgh	present for notes 3b
Huayi Huang	External researcher, University of Edinburgh	

4.0.03 DOC Cmte minutes

Apologies:	
Mohammed Irfaniq	Committee member
Ben Williams-Shaw	Lay member

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the second guideline committee meeting on gout.

The Chair introduced the two external researchers to the committee Bruce Guthrie and Huayi Huang who were presenting to the committee on the collaborative project with NICE on multimorbidity and clinical guidelines.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was

- The completion of protocol 4.5 from GC1. Prevention of gout flares during initiation or titration of ULT.
- ULT for first line treatment (protocol 4.2)

The Chair asked everyone to verbally declare any interests. There were no new declarations.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Presentations, questions and discussion

- a) Alexandra Bonnon presented on Health Economic prioritisation
- b) Bruce Guthrie presented on multimorbidity and clinical guidelines and led discussion with the committee
- c) The committee discussed and agreed the draft protocols for question:
4.5 clinical and cost-effectiveness of pharmacological interventions for the prevention of gout flares during initiation or titration of ULT

4.0.03 DOC Cmte minutes

4.2 In people with gout which urate-lowering therapies are the most clinically and cost effective for first-line treatment?

4. Any other business

None.

Date of next meeting: 30/10/20

Location of next meeting: Video-conference